论文部分内容阅读
目的:探讨布地奈德联合福莫特罗治疗慢性阻塞性肺疾病(COPD)合并感染患者的临床疗效。方法:选择2012年10月~2014年10月我院收治的COPD合并感染患者共84例,按照随机数字表法将患者随机分为试验组和对照组。两组患者均给予常规综合治疗,在此基础上对照组给予布地奈德,试验组在对照组治疗基础上联合福莫特罗,观察患者治疗前后血气功能、肺功能指标和临床疗效。结果:治疗后试验组Pa CO2显著低于对照组(P<0.05),Pa O2和Sa O2显著高于对照组(P<0.05)。治疗后试验组FEV1、FVC和FEV1/FVC均显著高于对照组(P<0.05)。实验组治疗后的总有效率为95.24%,显著高于对照组的78.57%(P<0.05)。结论:采用布地奈德和福莫特罗联合应用治疗COPD合并感染患者有协同效果,能够有效改善患者的血气指标、肺功能和临床效果,值得推广应用。
Objective: To investigate the clinical efficacy of budesonide combined with formoterol in patients with chronic obstructive pulmonary disease (COPD) complicated with infection. Methods: From October 2012 to October 2014, 84 patients with COPD complicated with infection in our hospital were randomly divided into experimental group and control group according to the random number table method. The two groups of patients were given conventional comprehensive treatment. On this basis, the control group was given budesonide. The experimental group was treated with formoterol on the basis of the control group, and the blood gas function, pulmonary function and clinical efficacy were observed before and after treatment. Results: After treatment, the PaCO 2 in the experimental group was significantly lower than that in the control group (P <0.05), Pa O2 and Sa O2 were significantly higher than those in the control group (P <0.05). After treatment, FEV1, FVC and FEV1 / FVC in the experimental group were significantly higher than those in the control group (P <0.05). The total effective rate of the experimental group after treatment was 95.24%, which was significantly higher than that of the control group (78.57%, P <0.05). Conclusion: The combination of budesonide and formoterol in the treatment of patients with COPD has synergistic effect, which can effectively improve the patients’ blood gas index, pulmonary function and clinical effect, which is worth popularizing and applying.